Commentary
Video
Author(s):
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024
Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
The OncFive: Top Oncology Articles for the Week of 2/2
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML
OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma
Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer
Potential Applications of Cancer Vaccines Continue to Expand in Squamous Cell Carcinoma
FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL
Over a Dozen FDA Approvals in 2024 Changed the Lung Cancer Field